Header Logo

Connection

WILLIAM K PLUNKETT JR to Arabinofuranosylcytosine Triphosphate

Back to Details
This is a "connection" page, showing publications WILLIAM K PLUNKETT JR has written about Arabinofuranosylcytosine Triphosphate.
WILLIAM K PLUNKETT JR
Connection Strength
1.872
Arabinofuranosylcytosine Triphosphate
  1. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997 Sep; 3(9):1539-45.
    View in: PubMed
    Score: 0.155
  2. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8.
    View in: PubMed
    Score: 0.126
  3. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993; 10 Suppl:109-14.
    View in: PubMed
    Score: 0.112
  4. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia. 1990 Feb; 4(2):95-9.
    View in: PubMed
    Score: 0.092
  5. Pharmacologically directed design of leukemia therapy. Haematol Blood Transfus. 1990; 33:610-3.
    View in: PubMed
    Score: 0.091
  6. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood. 1989 Nov 01; 74(6):2070-5.
    View in: PubMed
    Score: 0.090
  7. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988 Jan 15; 48(2):329-34.
    View in: PubMed
    Score: 0.080
  8. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007 Dec; 323(3):935-45.
    View in: PubMed
    Score: 0.078
  9. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1987 Jun 01; 47(11):3005-11.
    View in: PubMed
    Score: 0.076
  10. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol. 1987 Jun; 14(2 Suppl 1):159-66.
    View in: PubMed
    Score: 0.076
  11. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rep. 1987 May; 71(5):479-83.
    View in: PubMed
    Score: 0.076
  12. Pharmacokinetics of the 5'-triphosphates of arabinosylcytosine and 2',2'-difluorodeoxycytidine in L1210 cells. Nucleic Acids Symp Ser. 1987; (18):77-9.
    View in: PubMed
    Score: 0.074
  13. Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate. Cancer Res. 1986 Mar; 46(3):1079-83.
    View in: PubMed
    Score: 0.070
  14. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine. Scand J Haematol Suppl. 1986; 44:51-9.
    View in: PubMed
    Score: 0.069
  15. Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C. Adv Exp Med Biol. 1986; 195 Pt B:171-5.
    View in: PubMed
    Score: 0.069
  16. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol. 1985 Jun; 12(2 Suppl 3):20-30.
    View in: PubMed
    Score: 0.066
  17. Simultaneous determination of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 3-deazauridine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatogr. 1980 Dec 12; 221(2):425-30.
    View in: PubMed
    Score: 0.049
  18. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1980 Mar; 40(3):588-91.
    View in: PubMed
    Score: 0.046
  19. Intracellular pharmacodynamics in leukemia therapy. Rinsho Ketsueki. 1996 May; 37(5):369-79.
    View in: PubMed
    Score: 0.035
  20. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996 Jan 01; 87(1):256-64.
    View in: PubMed
    Score: 0.035
  21. Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol. 1994; 370:119-24.
    View in: PubMed
    Score: 0.030
  22. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994; 34(1):30-6.
    View in: PubMed
    Score: 0.030
  23. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma. 1993 May; 10(1-2):43-8.
    View in: PubMed
    Score: 0.029
  24. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leuk Lymphoma. 1993; 10 Suppl:115-21.
    View in: PubMed
    Score: 0.028
  25. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol. 1992; 31(1):11-7.
    View in: PubMed
    Score: 0.026
  26. Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol. 1991; 309A:125-30.
    View in: PubMed
    Score: 0.024
  27. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol. 1989 Oct 15; 38(20):3551-8.
    View in: PubMed
    Score: 0.023
  28. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol. 1989 May; 7(5):622-8.
    View in: PubMed
    Score: 0.022
  29. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988 Jul 15; 48(14):4024-31.
    View in: PubMed
    Score: 0.021
  30. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1985 Nov; 45(11 Pt 2):5952-7.
    View in: PubMed
    Score: 0.017
  31. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002 Oct 15; 20(20):4217-24.
    View in: PubMed
    Score: 0.014
  32. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9.
    View in: PubMed
    Score: 0.009
  33. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996 Apr; 2(4):653-8.
    View in: PubMed
    Score: 0.009
  34. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia. 1987 Sep; 1(9):638-43.
    View in: PubMed
    Score: 0.005
  35. Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. Semin Oncol. 1987 Jun; 14(2 Suppl 1):58-63.
    View in: PubMed
    Score: 0.005
  36. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol. 1986; 18(2):145-52.
    View in: PubMed
    Score: 0.004
  37. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104.
    View in: PubMed
    Score: 0.004
  38. High-dose cytosine arabinoside in multiple myeloma. Eur J Cancer Clin Oncol. 1984 Feb; 20(2):227-31.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.